AstraZeneca Pharma India, a drug firm, has announced that it received green signal from Drug Controller General of India (DCGI) to import and market olaparib tablets.
The tablets are used to treat patients suffered with ovarian and breast cancer.
DCGI gave its go-ahead for olaparib (Lynparza) tablets in the strengths of 100 mg and 150 mg, AstraZeneca Pharma India said in a BSE filing.
The tablets are a patented product of the AstraZeneca group, it added.
Responding to the development, Gagan Singh, Managing Director, AstraZeneca Pharma India, said, “The import and market permission for olaparib is a significant milestone for women in India living with platinum-sensitive relapsed ovarian cancer and BRCA-mutated HER-2 negative metastatic breast cancer, which has historically been difficulty-to-treat diseases.”